Canada
· Delayed Price · Currency is CAD Cannara Biotech Statistics
Total Valuation
Cannara Biotech has a market cap or net worth of CAD 116.12 million. The enterprise value is 159.93 million.
| Market Cap | 116.12M |
| Enterprise Value | 159.93M |
Important Dates
The next estimated earnings date is Friday, July 18, 2025.
| Earnings Date | Jul 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cannara Biotech has 91.43 million shares outstanding. The number of shares has increased by 1.66% in one year.
| Current Share Class | 91.43M |
| Shares Outstanding | 91.43M |
| Shares Change (YoY) | +1.66% |
| Shares Change (QoQ) | +0.74% |
| Owned by Insiders (%) | 2.34% |
| Owned by Institutions (%) | 0.13% |
| Float | 44.71M |
Valuation Ratios
The trailing PE ratio is 9.15.
| PE Ratio | 9.15 |
| Forward PE | n/a |
| PS Ratio | 1.23 |
| PB Ratio | 1.23 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | 25.61 |
| P/OCF Ratio | 10.76 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.08, with an EV/FCF ratio of 35.27.
| EV / Earnings | 11.94 |
| EV / Sales | 1.70 |
| EV / EBITDA | 7.08 |
| EV / EBIT | 9.93 |
| EV / FCF | 35.27 |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.52.
| Current Ratio | 2.35 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 2.16 |
| Debt / FCF | 10.78 |
| Interest Coverage | 3.55 |
Financial Efficiency
Return on equity (ROE) is 15.44% and return on invested capital (ROIC) is 7.41%.
| Return on Equity (ROE) | 15.44% |
| Return on Assets (ROA) | 6.55% |
| Return on Invested Capital (ROIC) | 7.41% |
| Return on Capital Employed (ROCE) | 12.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.33 |
Taxes
In the past 12 months, Cannara Biotech has paid 188,392 in taxes.
| Income Tax | 188,392 |
| Effective Tax Rate | 1.39% |
Stock Price Statistics
The stock price has increased by +95.71% in the last 52 weeks. The beta is 0.23, so Cannara Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +95.71% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 1.01 |
| Relative Strength Index (RSI) | 60.58 |
| Average Volume (20 Days) | 60,134 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cannara Biotech had revenue of CAD 94.07 million and earned 13.40 million in profits. Earnings per share was 0.14.
| Revenue | 94.07M |
| Gross Profit | 39.38M |
| Operating Income | 16.10M |
| Pretax Income | 13.59M |
| Net Income | 13.40M |
| EBITDA | 22.29M |
| EBIT | 16.10M |
| Earnings Per Share (EPS) | 0.14 |
Balance Sheet
The company has 5.06 million in cash and 48.86 million in debt, giving a net cash position of -43.81 million or -0.48 per share.
| Cash & Cash Equivalents | 5.06M |
| Total Debt | 48.86M |
| Net Cash | -43.81M |
| Net Cash Per Share | -0.48 |
| Equity (Book Value) | 94.19M |
| Book Value Per Share | 1.03 |
| Working Capital | 43.16M |
Cash Flow
In the last 12 months, operating cash flow was 10.80 million and capital expenditures -6.26 million, giving a free cash flow of 4.53 million.
| Operating Cash Flow | 10.80M |
| Capital Expenditures | -6.26M |
| Free Cash Flow | 4.53M |
| FCF Per Share | 0.05 |
Margins
Gross margin is 41.86%, with operating and profit margins of 17.12% and 14.24%.
| Gross Margin | 41.86% |
| Operating Margin | 17.12% |
| Pretax Margin | 14.44% |
| Profit Margin | 14.24% |
| EBITDA Margin | 23.70% |
| EBIT Margin | 17.12% |
| FCF Margin | 4.82% |
Dividends & Yields
Cannara Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.66% |
| Shareholder Yield | n/a |
| Earnings Yield | 11.54% |
| FCF Yield | 3.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cannara Biotech has an Altman Z-Score of 1.8 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.8 |
| Piotroski F-Score | 5 |